AIRNA Presents New Preclinical Data on AATD Therapeutic Candidate AIR-001 and Cardiometabolic RNA-Editing Programs at ASGCT

– AIR-001 demonstrated best-in-class potential, achieving up to 59% precise RNA editing in vivo and restoring 40 µM functional M-AAT in a mouse model of AATD – Preclinical data show RNA editing can introduce protective variants for cardiovascular disease and drive reduction of LDL cholesterol levels CAMBRIDGE, Mass., May 12, 2026 – AIRNA, a biotech […] The post AIRNA Presents New Preclinical Data on AATD Therapeutic Candidate AIR-001 and Cardiometabolic RNA-Editing Programs at ASGCT appeared first on Airna .